Analyze the Commercial Potential for Sanctura XR, A Recently-Approved Next-Generation Overactive Bladder Agent
Business Wire, Sept 27, 2006
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42806
) has announced the addition of the new report from Datamonitor "Financial Markets Research: Indevus Pharmaceuticals Sanctura XR - Last-to-market Entrant Unlikely to Make an Impact in Crowded OAB Market" to their offering.
The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XRs near-term potential.
Related Results: sanctura xr
Indevus Initiates Phase III
Clinical Program for SANCTURA... More
Motorsports video - klx crf xr...
Scope of this title:
This title analyzes the commercial potential for IDEVs Sanctura XR, a recently-approved next-generation OAB agent. For this report we interviewed twenty-four urologists regarding trends in the treatment of OAB and the potential role of next-generation Sanctura XR
Highlights of this title include:
Based on the data from the Phase II trial, we anticipate that once-daily Sanctura XR will demonstrate a safety and efficacy profile comparable to the original twice-daily Sanctura formulation and support its FDA approval in mid/late 2007.
Interviewed physicians indicated that all currently marketed OAB products have comparable safety and efficacy profiles and, as the last once-daily OAB option to come to market, if approved, Sanctura XR would not dramatically impact their OAB prescribing habits given the crowded OAB market.